120373-36-6
120373-36-6 结构式
基本信息
Unii-6X4F561V3w
Unoprostone [inn]
13,14-DIHYDRO-15-KETO-20-ETHYL PROSTAGLANDIN F2ALPHA
9ALPHA, 11ALPHA-DIHYDROXY-15-OXO-20A,20B-DIHOMOPROST-5-EN-1-OIC ACID
(E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoic acid
5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, (5Z)-
物理化学性质
常见问题列表
Pretreatment with Unoprostone (0.01, 0.1, 1 μM; 1 h before H
2
O
2
treatment) protects against H
2
O
2
-induced cell death in a concentration-dependent manner and the effect is significant at 0.1 μM and 1 μM concentrations.
Pretreatment with Unoprostone at concentrations of 0.1 to 3 μM protects against light-induced cell death in a concentration-dependent manner; the effect is significant at the 1 and 3 μM concentrations. Unoprostone reduces the morphological change, and it significantly inhibits the low mitochondrial membrane potential and cell death induced by light irradiation.
Unoprostone has prostaglandin F
2α
receptors (FP) binding affinity with a K
i
of 3.86 μM.
Cell Viability Assay
| Cell Line: | H 2 O 2 -induced photoreceptor cell |
| Concentration: | 0.01, 0.1, 1 μM |
| Incubation Time: | 1 hour before H 2 O 2 treatment |
| Result: | Protected against H 2 O 2 -induced cell death in a concentration-dependent manner. |
Unoprostone (0.06%, 0.12%; topical instillation; 3 µl) reduces mouse intraocular pressure (IOP) in a dose-dependent manner.
| Animal Model: | Male mice (6 weeks old) |
| Dosage: | 0.06%, 0.12% |
| Administration: | Topical instillation; 3 µl |
| Result: | Reduced mouse IOP in a dose-dependent manner. |